Adhera Therapeutics (Adhera Therapeutics) Cash per Share : $0.01 (As of Sep. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Adhera Therapeutics Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Adhera Therapeutics's Cash per Share for the quarter that ended in Sep. 2023 was $0.01.

Adhera Therapeutics Cash per Share Historical Data

The historical data trend for Adhera Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adhera Therapeutics Cash per Share Chart

Adhera Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash per Share

Get a 7-Day Free Trial

7.28

0.09

0.01

Adhera Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash per Share	Get a 7-Day Free Trial															0.04	0.01	0.02	0.02	0.01

Adhera Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Adhera Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	0.032	/	3.16
	=	0.01

Adhera Therapeutics's Cash per Share for the quarter that ended in Sep. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	0.032	/	5.17
	=	0.01

Adhera Therapeutics (OTCPK:ATRX) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Adhera Therapeutics Cash per Share Related Terms

Thank you for viewing the detailed overview of Adhera Therapeutics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Adhera Therapeutics (Adhera Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adhera Therapeutics Inc (OTCPK:ATRX) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

8000 Innovation Parkway, Baton Rouge, LA, USA, 70820

Website

https://www.adherathera.com

Adhera Therapeutics Inc is an emerging specialty biotech company that is strategically evaluating its focus including a return to a drug discovery and development company.

Executives

Zahed Subhan	director	8000 INNOVATION PARKWAY, BATON ROUGE LA 70820
Trond Kydd Waerness	director	8000 INNOVATION PARKWAY, BAON ROUGE LA 70820
Rice Charles L Jr	director	C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk	director, officer: Chief Executive Officer	549 MILGATE PLACE, BATON ROUGE LA 70810
Rhonda L. Stanley	officer: SVP Finance & Accounting	5001 SOUTH MIAMA BOULEVARD, SUITE 300, DURHAM NC 27703
Nancy R. Phelan	director	812 MAPLEWOOD ROAD, WAYNE PA 19087
Robert Eric Teague	officer: Chief Financial Officer	C/O MARINA BIOTECH, INC., 4721 EMPEROR BOULEVARD, SUITE 350, DURHAM NC 27703
Uli Hacksell	director	3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Robert Jr. Moscato	officer: CEO	400 PRATT STREET, SUITE 606, BALTIMORE MD 21202
Timothy Boris	director	805 AEROVISTA PLACE, SUITE 205, SAN LUIS OBISPO CA 93401
Isaac Blech	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Peter D. Weinstein	officer: Chief Legal Officer	C.O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Amit B. Shah	officer: Chief Financial Officer	10 AGUILA, ALISO VIEJO CA 92656
Erik C. Emerson	officer: Chief Commercial Officer	2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS NV 89102
Mihir Munsif	officer: Chief Operating Officer	21102 BRIARWOOD LANE, TRABUCO CANYON CA 92679